Breast Imaging Industry Overview

The global breast imaging market size was valued at USD 4.7 billion in 2022 and is projected to expand at a compound annual growth rate (CAGR) of 8.6% from 2023 to 2030.

Factors such as the rising prevalence of breast cancer, technological breakthroughs in the domain of breast imaging, and investment from several organizations in breast cancer screening programs drive the market. According to the World Cancer Research Fund (WCRF) by 2030, the number of cases of breast cancer is likely to reach about 2.1 million globally. Also, as per the World Health Organization report on breast cancer released in March 2021, over 2.3 million women globally were diagnosed with the disease in 2020, with approximately 685,000 dying as a result of its severity. Breast imaging is the primary method of diagnosis for a vast majority of breast cancer patients globally. This aspect is expected to contribute to the growth of the market during the forecast period.

Gather more insights about the market drivers, restrains and growth of the Breast Imaging Market

These screening programs have been shown to save lives compared to unscreened populations. Thus, rising screening programs and government initiatives are anticipated to upsurge the awareness associated with the diagnosis and treatment of breast cancer and thus might eventually aid the breast imaging market growth. Widespread research in the development of hybrid imaging systems provides high growth opportunities and also aids market growth. Recent developments in imaging technology have completely revolutionized the nature of treatment and the way it is approached.

To view the metabolic data and anatomical characteristics of the organs, it has become more crucial to combine imaging methods like CT scans, MRIs, PET, and others. Furthermore, the quality of breast pictures, patient comfort, and patient dose have all been enhanced by these integrated imaging modalities. Thereby, owing to these advantages, manufacturers across the globe are concentrating more on the introduction of new products to improve the sensitivity and precision of breast cancer diagnostics. For Instance, in January 2021, Seno Medical Instruments obtained premarket approval from The Center for Devices and Radiological Health in the U.S. for its diagnostic breast cancer imaging technology. The novel technology specialized in differentiating malignant and benign breast lesions.

The adoption of highly sophisticated imaging methods and systems for breasts as well as advances in the detection of breast cancer are predicted to accelerate market expansion. Hence owing to the aforementioned factors, the market is anticipated to propel at high growth rates. However, the high cost of imaging systems and the adverse effects of radiation exposure are expected to hinder the growth of the studied market in the forecast period.

The Russia-Ukraine war has severely impacted the health system due to damage to health infrastructures such as hospitals and clinics. Due to storage space issues and the expense of maintaining a big inventory, the majority of hospitals rarely have supplies of medications and consumables that last longer than a few days. Particularly commodities required for treating war injuries, such as antibiotics, blood supplies, and wound dressings, are exhausted from these stocks. It will be extremely challenging to provide in Ukraine, and it will be challenging to determine the entire degree of the interruption to the health system, especially since cyberattacks have affected IT systems. This is made worse by the ongoing COVID epidemic, which has about 1,700 patients now being treated in hospitals across the nation, as stated by a press release published in OCHA, reliefweb, March 2022.

Browse through Grand View Research's Medical Devices Industry Research Reports.

  • The global breast cancer diagnostics market size was valued at USD 4.3 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 7.4% from 2023 to 2030.
  • The global mammography market size was valued at USD 2.35 billion in 2023 and is projected to grow at a CAGR of 8.87% from 2024 to 2030.

Breast Imaging Market Segmentation

Grand View Research has segmented the global breast imaging market based on technology, end-use, and region:

Breast Imaging Technology Outlook (Revenue, USD Million; 2018 - 2030)

  • Ionizing
    • Full-field Digital Mammography
    • Analog Mammography
    • Positron Emission Mammography
    • Electric Impedance Tomography
    • Cone-Beam Computed Tomography
    • Positron Emission Tomography & Computed Tomography
    • 3D Breast Tomosynthesis
    • MBI/BSGI
  • Non-ionizing
    • MRI
    • Thermography
    • Ultrasound
    • Optical Imaging
    • Automated Whole-breast Ultrasound

Breast Imaging End-use Outlook (Revenue, USD Million; 2018 - 2030)

  • Hospitals
  • Breast Care Centers
  • Diagnostic Imaging Centers

Breast Imaging Regional Outlook (Revenue, USD Million; 2018 - 2030)

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • India
    • China
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Mexico
    • Brazil
    • Argentina
  • MEA
    • South Africa
    • Saudi Arabia
    • Kuwait
    • UAE

Key Companies profiled:

  • GE Healthcare,
  • Hologic, Inc.,
  • Philips Healthcare
  • Gamma Medica, Inc.
  • Siemens Healthcare
  • Fujifilm Holdings Corp.
  • SonoCine, Inc.,
  • Toshiba Corporation,
  • Dilon Technologies, Inc.,
  • Aurora Imaging Technology, Inc.

Recent Developments

  • In May 2022, QUSTom (Quantitative Ultrasound Stochastic Tomography), a new European project, was coordinated by the Barcelona Supercomputing Center (BSC). QUSTom aims to develop a new medical imaging modality based on ultrasound and supercomputing that will supplement or even replace current X-ray-based techniques such as mammograms.
  • In March 2022, researchers at the University of Notre Dame designed a novel imaging device, NearWave Imager, for non-invasive breast cancer detection.
  • In June 2022, GE Healthcare join forces with the National Cancer Centre Singapore (NCCS). This partnership seeks to stimulate the possibility of more personalized treatment options for cancer and provide the opportunity to examine clinically vital information during the patient journey by leveraging artificial intelligence and text processing.

Order a free sample PDF of the Breast Imaging Market Intelligence Study, published by Grand View Research.

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.